Summary:
To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of schizophrenia.
Qualified Participants Must:
• Be 18 years of age and older (Adult, Senior)
•
Have a clinical diagnosis of schizophrenia with a minimum duration of 1 year
•
Live within 100 miles of the study location (within the greater Los Angeles area)
Qualified Participants May Receive:
Qualified participants may receive compensation for time and travel. for more information on compensation please contact CNS.